Sector News

UCB sells generics unit Kremers Urban for $1.53 billion

November 7, 2014
Life sciences
UCB is selling its US specialty generics business Kremers Urban Pharmaceuticals to two private equity groups for almost $1.53 billion.
 
The cash from Advent International and Avista Capital Partners will be used by Belgium-headquartered UCB “to reduce indebtedness and increase the company’s capacity strategic investments”. The deal is expected to close by the first quarter of 2015.
 
Kremers Urban focuses on difficult, ‘high-barrier-to-entry’ generics and UCB got hold of the New Jersey-based business through its acquisition of Schwarz Pharma in 2006.
 
UCB chief financial officer Detlef Thielgen said it “has been an important enabler” to build the group’s operations. However, “it’s now the right time from a value perspective to focus on our core business” of neurology and immunology.
 
The sale was announced after another Belgian firm, the over-the-counter group Omega Pharma, announced it was being acquired by Perrigo in a deal worth $4.5 billion.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend